Ma Somsouk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ma Somsouk has a total of 398 co-authors. Here are the top co-authors by number of shared publications:
Carly Rachocki
Alameda County Behavioral Health, Oakland, California
10 shared publications- Steven Deeks
Department of Medicine, University of California San Francisco, San Francisco, USA
10 shared publications - John M. Inadomi
Department of Internal Medicine, The University of Utah School of Medicine, Salt Lake City, Utah, USA
9 shared publications Eric Vittinghoff
Alameda County Behavioral Health, Oakland, California
7 shared publicationsEllen Chen
San Francisco Health Network, San Francisco, California
6 shared publicationsNajwa El-Nachef
6 shared publications
Latest Publications
- Open Access
Multilevel Interventions to Improve Colonoscopy Completion After Abnormal Fecal Immunochemical Testing in a Safety-Net Health System: Preliminary Findings from the IMPACTT Study
Background: Timely diagnostic colonoscopy is a critical step after an abnormal fecal immunochemical test (FIT), yet many patients do not complete follow-up within recommended timeframes, particularly in safety-net settings. Barriers occur across multiple levels and stages of care, suggesting a need for interventions that address both clinic processes and patient-level barriers. Methods: IMProving Adherence to Colonoscopy through Teams and Technology (IMPACTT) evaluated two concurrent interventions across 12 adult primary care clinics in the San Francisco Health Network. A clinic-level Best Practice Bundle (BPB), implemented in a stepped-wedge rollout, included patient tracking, standardized electronic health record documentation, standardized education and communication, and audit and feedback. In parallel, we randomly assigned eligible patients to a patient-level instruction and navigation (PIN) intervention or usual care. PIN provided targeted outreach to patients who were neither referred nor scheduled, as well as multilingual text reminders that allowed patients to confirm, cancel, or reschedule their colonoscopy. The primary outcome was colonoscopy completion within 180 days of an abnormal FIT. This preliminary analysis reports unadjusted comparisons among patients with sufficient follow-up at the data cutoff. Results: Among 2,303 patients with an abnormal FIT, 1,136 were identified before and 1,167 after their clinic implemented the BPB. Colonoscopy completion within 180 days was 44.1% before BPB implementation and 60.1% after implementation (risk difference, 16.0 percentage points; 95% CI, 11.8 to 20.1; p<0.001). Referral to gastroenterology within 42 days increased from 69.8% to 84.2%, and among patients who completed colonoscopy, the median time from FIT to colonoscopy decreased from 131 to 86 days. In the randomized PIN trial, we assigned 1,415 patients to usual care (n=698) or PIN (n=717). Colonoscopy completion within 180 days did not differ between usual care and PIN (58.4% vs 57.7%; risk difference, -0.7 percentage points; 95% CI, -5.9 to 4.6; p=0.9). PIN also did not improve referral within 42 days or scheduling within 56 days. Conclusions: In preliminary unadjusted analyses, implementation of a clinic-level bundle targeting tracking, communication, documentation, and feedback was associated with improved timely follow-up after abnormal FIT, whereas a randomized technology-supported patient instruction and navigation intervention did not improve colonoscopy completion. Prespecified analyses accounting for calendar time, clinic-level clustering, patient characteristics, and concurrent intervention assignment are forthcoming. Trial registration: ClinicalTrials.gov NCT06191185 .
Open AccessMultilevel Interventions to Improve Colonoscopy Completion After Abnormal Fecal Immunochemical Testing in a Safety-Net Health System: Preliminary Findings from the IMPACTT Study
Background: Timely diagnostic colonoscopy is a critical step after an abnormal fecal immunochemical test (FIT), yet many patients do not complete follow-up within recommended timeframes, particularly in safety-net settings. Barriers occur across multiple levels and stages of care, suggesting a need for interventions that address both clinic processes and patient-level barriers. Methods: IMProving Adherence to Colonoscopy through Teams and Technology (IMPACTT) evaluated two concurrent interventions across 12 adult primary care clinics in the San Francisco Health Network. A clinic-level Best Practice Bundle (BPB), implemented in a stepped-wedge rollout, included patient tracking, standardized electronic health record documentation, standardized education and communication, and audit and feedback. In parallel, we randomly assigned eligible patients to a patient-level instruction and navigation (PIN) intervention or usual care. PIN provided targeted outreach to patients who were neither referred nor scheduled, as well as multilingual text reminders that allowed patients to confirm, cancel, or reschedule their colonoscopy. The primary outcome was colonoscopy completion within 180 days of an abnormal FIT. This preliminary analysis reports unadjusted comparisons among patients with sufficient follow-up at the data cutoff. Results: Among 2,303 patients with an abnormal FIT, 1,136 were identified before and 1,167 after their clinic implemented the BPB. Colonoscopy completion within 180 days was 44.1% before BPB implementation and 60.1% after implementation (risk difference, 16.0 percentage points; 95% CI, 11.8 to 20.1; p<0.001). Referral to gastroenterology within 42 days increased from 69.8% to 84.2%, and among patients who completed colonoscopy, the median time from FIT to colonoscopy decreased from 131 to 86 days. In the randomized PIN trial, we assigned 1,415 patients to usual care (n=698) or PIN (n=717). Colonoscopy completion within 180 days did not differ between usual care and PIN (58.4% vs 57.7%; risk difference, -0.7 percentage points; 95% CI, -5.9 to 4.6; p=0.9). PIN also did not improve referral within 42 days or scheduling within 56 days. Conclusions: In preliminary unadjusted analyses, implementation of a clinic-level bundle targeting tracking, communication, documentation, and feedback was associated with improved timely follow-up after abnormal FIT, whereas a randomized technology-supported patient instruction and navigation intervention did not improve colonoscopy completion. Prespecified analyses accounting for calendar time, clinic-level clustering, patient characteristics, and concurrent intervention assignment are forthcoming. Trial registration: ClinicalTrials.gov NCT06191185 .
- Open Access
- 30 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
SARS-CoV-2-specific monoclonal antibody AER002 in Long COVID: an exploratory randomized phase 2a mechanistic trial
Persistence of SARS-CoV-2 has been proposed as a biological driver of Long COVID, a disabling chronic illness with no proven treatments. We conducted an exploratory, placebo-controlled, double-blind, 2:1 randomized mechanistic trial (NCT05877508) of the SARS-CoV-2-specific monoclonal antibody AER002 in 36 participants who met the World Health Organization case definition of Long COVID. After baseline characterization, participants received a single infusion and were followed for 360 days. The primary endpoint was the PROMIS-29 Physical Health Summary Score (PHSS) at 90 days; secondary and exploratory endpoints included patient-reported and objective measures of physical and neurocognitive function as well as blood-, imaging-, and tissue-based biomarkers. While AER002 was safe and well tolerated, no significant differences in physical health, quality of life, objective measures of physical function or cognition, or blood-based biomarkers were demonstrated between the treatment and control arms. In a post-hoc analysis, participants with a lower baseline SARS-CoV-2 antibody level and higher drug exposure were more likely to perceive treatment benefit based on the Patient Global Impression of Change scale ( p < 0.05 for anti-S, S1, and RBD). Although AER002 was not efficacious in this proof-of-concept study, our findings could inform future trials using monoclonal antibodies to target viral persistence in Long COVID.
- 30 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessSARS-CoV-2-specific monoclonal antibody AER002 in Long COVID: an exploratory randomized phase 2a mechanistic trial
Persistence of SARS-CoV-2 has been proposed as a biological driver of Long COVID, a disabling chronic illness with no proven treatments. We conducted an exploratory, placebo-controlled, double-blind, 2:1 randomized mechanistic trial (NCT05877508) of the SARS-CoV-2-specific monoclonal antibody AER002 in 36 participants who met the World Health Organization case definition of Long COVID. After baseline characterization, participants received a single infusion and were followed for 360 days. The primary endpoint was the PROMIS-29 Physical Health Summary Score (PHSS) at 90 days; secondary and exploratory endpoints included patient-reported and objective measures of physical and neurocognitive function as well as blood-, imaging-, and tissue-based biomarkers. While AER002 was safe and well tolerated, no significant differences in physical health, quality of life, objective measures of physical function or cognition, or blood-based biomarkers were demonstrated between the treatment and control arms. In a post-hoc analysis, participants with a lower baseline SARS-CoV-2 antibody level and higher drug exposure were more likely to perceive treatment benefit based on the Patient Global Impression of Change scale ( p < 0.05 for anti-S, S1, and RBD). Although AER002 was not efficacious in this proof-of-concept study, our findings could inform future trials using monoclonal antibodies to target viral persistence in Long COVID.
- Open Access
Multiomic and Spatial Profiling of Colorectal Tissue Reveals Viral Persistence and Immune Dysregulation in Long COVID
Long COVID (LC) – a chronic condition characterized by persistent, debilitating symptoms following SARS-CoV-2 infection – has emerged as a major public health challenge. Although many interrelated mechanisms have been proposed as drivers of LC, the root causes have yet to be identified, posing significant challenges for therapeutic development. While many blood-based studies have been conducted, they have not yielded conclusive mechanistic insights into LC pathogenesis. Attention has therefore turned toward direct tissue investigation, with the gastrointestinal (GI) tract becoming a major focus due to evidence that virus or viral components can persist at this site for months to years following an episode of COVID-19. Here, we performed a high-dimensional characterization of colorectal tissue and peripheral blood in a highly characterized cohort of 44 people with LC and 13 recovered controls. We profiled SARS-CoV-2 persistence, host immune responses, and tissue inflammation using bulk and single-cell RNA sequencing, nCounter RNA probe hybridization, quantitative PCR, metagenomic next-generation sequencing, plasma proteomics, high-dimensional spectral flow cytometry, in situ-hybridization/immunohistochemistry, and single-cell digital spatial omics. Our results support a model in which LC is driven by long-term immune dysregulation and perturbations of the regulatory gut immune environment which imply ongoing viral persistence, although direct viral detection was only observed in a subset of participants. Specifically, we identify a tissue-based transcriptional environment in which SARS-CoV-2 activates innate myeloid immune signaling, driving chronic inflammation while simultaneously downregulating pathways responsible for immune-mediated clearance of infected cells, including antigen presentation, phagocytosis, cytotoxic immune cell trafficking, and granzyme production. Importantly, signatures in peripheral blood are considerably weaker than those observed in tissue. Together, these findings provide a direct biological rationale for therapeutic strategies in LC aimed at enhancing or redirecting cytotoxic immune function to overcome immune dysregulation and clear persistent viral reservoirs.
Open AccessMultiomic and Spatial Profiling of Colorectal Tissue Reveals Viral Persistence and Immune Dysregulation in Long COVID
Long COVID (LC) – a chronic condition characterized by persistent, debilitating symptoms following SARS-CoV-2 infection – has emerged as a major public health challenge. Although many interrelated mechanisms have been proposed as drivers of LC, the root causes have yet to be identified, posing significant challenges for therapeutic development. While many blood-based studies have been conducted, they have not yielded conclusive mechanistic insights into LC pathogenesis. Attention has therefore turned toward direct tissue investigation, with the gastrointestinal (GI) tract becoming a major focus due to evidence that virus or viral components can persist at this site for months to years following an episode of COVID-19. Here, we performed a high-dimensional characterization of colorectal tissue and peripheral blood in a highly characterized cohort of 44 people with LC and 13 recovered controls. We profiled SARS-CoV-2 persistence, host immune responses, and tissue inflammation using bulk and single-cell RNA sequencing, nCounter RNA probe hybridization, quantitative PCR, metagenomic next-generation sequencing, plasma proteomics, high-dimensional spectral flow cytometry, in situ-hybridization/immunohistochemistry, and single-cell digital spatial omics. Our results support a model in which LC is driven by long-term immune dysregulation and perturbations of the regulatory gut immune environment which imply ongoing viral persistence, although direct viral detection was only observed in a subset of participants. Specifically, we identify a tissue-based transcriptional environment in which SARS-CoV-2 activates innate myeloid immune signaling, driving chronic inflammation while simultaneously downregulating pathways responsible for immune-mediated clearance of infected cells, including antigen presentation, phagocytosis, cytotoxic immune cell trafficking, and granzyme production. Importantly, signatures in peripheral blood are considerably weaker than those observed in tissue. Together, these findings provide a direct biological rationale for therapeutic strategies in LC aimed at enhancing or redirecting cytotoxic immune function to overcome immune dysregulation and clear persistent viral reservoirs.
- Open Access
- 30 June 2026
- Published by SAGE Publications in Cancer Control
- Vol. 33
Clinical Diagnosis Codes Identify Patients Unlikely to Receive Orders for Fecal Immunochemical Tests
Introduction: Automated colorectal cancer (CRC) screening programs often invite all age-eligible patients for fecal immunochemical testing (FIT), but providers may defer screening in clinically complex patients. However, such nuanced decisions are not captured by most automated systems. We evaluated whether International Classification of Diseases, Tenth Revision (ICD-10) codes are associated with variations in FIT ordering patterns beyond age-based outreach criteria. Methods: In a retrospective observational study of 15,020 screening-eligible patients aged 50-75, we compared the frequency of ICD-10 codes between patients with and without a FIT order. We repeated the analysis restricted to those with a Charlson Comorbidity Index (CCI)<5. Results: Overall, 4,833 (32.2%) patients did not have a FIT order. Of the 1,215 ICD-10 codes examined, 96 were significantly associated with the absence of a FIT order (p<0.05). These codes frequently indicated digestive diseases (e.g., colonic neoplasm, diverticular disease), advanced comorbidities (e.g., frailty, paralysis), and acute conditions (e.g., fractures, severe infections). Among the patients with CCI<5, 41 codes were associated with the absence of a FIT order (p<0.05), such as heart failure and chronic kidney disease. Conclusion: Screening-eligible patients without a FIT order were more likely to have ICD-10 codes reflecting digestive diseases, chronic comorbidities, and acute conditions. These findings demonstrate that specific diagnostic profiles are associated with real-world FIT ordering patterns, highlighting the need for further investigation into how comorbidities and competing clinical priorities relate to CRC screening decisions.
- 30 June 2026
- Published by SAGE Publications in Cancer Control
- Vol. 33
Open AccessClinical Diagnosis Codes Identify Patients Unlikely to Receive Orders for Fecal Immunochemical Tests
Introduction: Automated colorectal cancer (CRC) screening programs often invite all age-eligible patients for fecal immunochemical testing (FIT), but providers may defer screening in clinically complex patients. However, such nuanced decisions are not captured by most automated systems. We evaluated whether International Classification of Diseases, Tenth Revision (ICD-10) codes are associated with variations in FIT ordering patterns beyond age-based outreach criteria. Methods: In a retrospective observational study of 15,020 screening-eligible patients aged 50-75, we compared the frequency of ICD-10 codes between patients with and without a FIT order. We repeated the analysis restricted to those with a Charlson Comorbidity Index (CCI)<5. Results: Overall, 4,833 (32.2%) patients did not have a FIT order. Of the 1,215 ICD-10 codes examined, 96 were significantly associated with the absence of a FIT order (p<0.05). These codes frequently indicated digestive diseases (e.g., colonic neoplasm, diverticular disease), advanced comorbidities (e.g., frailty, paralysis), and acute conditions (e.g., fractures, severe infections). Among the patients with CCI<5, 41 codes were associated with the absence of a FIT order (p<0.05), such as heart failure and chronic kidney disease. Conclusion: Screening-eligible patients without a FIT order were more likely to have ICD-10 codes reflecting digestive diseases, chronic comorbidities, and acute conditions. These findings demonstrate that specific diagnostic profiles are associated with real-world FIT ordering patterns, highlighting the need for further investigation into how comorbidities and competing clinical priorities relate to CRC screening decisions.
- Open Access
- 5 May 2026
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 9 (3) , ooag106
Large language model chatbot-based text-to-SQL application for database analyses in liver diseases and hepatology research
Objective: Large language models (LLMs) may improve analysis of structured clinical data by enabling natural language (NL) queries. We developed an interactive, PHI-compliant “Text2SQL” chatbot as a proof-of-concept for hepatocellular carcinoma (HCC) research. Materials and methods: Using the University of California, San Francisco’s secure artificial intelligence platform, we configured the chatbot to translate NL queries into Structured Query Language (SQL), execute them, and return both code and results. Clinicians posed 30 questions, and outputs were compared with SQL written by a data scientist. We assessed prompt interpretation, SQL accuracy, output accuracy, and error types according to strict binary criteria. Results: Prompt interpretation accuracy was 73.3%, SQL accuracy ranged from 53% to 63%, and output accuracy from 53% to 63%. Frequent errors included group comparisons, ambiguous variables, and exploratory questions. Discussion: Text2SQL enables PHI-compliant interaction with clinical datasets without coding, though performance varies across query types. Conclusion: LLM-powered Text2SQL offers a promising approach for clinician-friendly clinical data access.
- 5 May 2026
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 9 (3) , ooag106
Open AccessLarge language model chatbot-based text-to-SQL application for database analyses in liver diseases and hepatology research
Objective: Large language models (LLMs) may improve analysis of structured clinical data by enabling natural language (NL) queries. We developed an interactive, PHI-compliant “Text2SQL” chatbot as a proof-of-concept for hepatocellular carcinoma (HCC) research. Materials and methods: Using the University of California, San Francisco’s secure artificial intelligence platform, we configured the chatbot to translate NL queries into Structured Query Language (SQL), execute them, and return both code and results. Clinicians posed 30 questions, and outputs were compared with SQL written by a data scientist. We assessed prompt interpretation, SQL accuracy, output accuracy, and error types according to strict binary criteria. Results: Prompt interpretation accuracy was 73.3%, SQL accuracy ranged from 53% to 63%, and output accuracy from 53% to 63%. Frequent errors included group comparisons, ambiguous variables, and exploratory questions. Discussion: Text2SQL enables PHI-compliant interaction with clinical datasets without coding, though performance varies across query types. Conclusion: LLM-powered Text2SQL offers a promising approach for clinician-friendly clinical data access.
- Open Access
- 1 May 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Estimated no-show rate from the electronic record strongly correlates with endoscopy no-show
Background: High demand for endoscopic procedures contributes to prolonged wait times and limited access to care, particularly in safety-net health systems. Missed appointments, including no-shows and late reschedules, further strain resources and delay diagnosis and treatment. Epic Systems provides a proprietary Risk of Patient No-Show Model, previously validated in primary care settings, but its performance in predicting attendance for endoscopy appointments has not been evaluated. Methods: A retrospective cohort study was conducted among adults scheduled for outpatient endoscopy at a single safety-net hospital between January 1, 2023, and August 1, 2024. Patients aged ≥ 18 years with at least one prior encounter in the electronic medical record (EMR) were included; inpatient procedures and early cancellations (> 2 days before the appointment) were excluded. The primary outcome was appointment completion versus no-show. Epic’s predicted no-show risk, demographic characteristics, procedure type, and patient portal activation status were extracted. The relationship between predicted and observed no-show rates was assessed using the coefficient of determination (R²) and linear regression. Secondary analyses stratified results by patient portal activation. Results: Among 4,658 unique patients, the median age was 59 years, 52.2% were male, and the cohort was racially and linguistically diverse. Overall, 1,493 patients (32.1%) did not attend their scheduled endoscopy. Epic’s predicted no-show risk demonstrated a strong linear correlation with actual no-show rates (R² = 0.87). Observed missed appointment rates followed the equation: Missed Appointment Rate = 1.30 × (Epic Risk) + 0.16 , indicating a baseline no-show rate of 16%. Each percentage-point increase in Epic’s predicted risk corresponded to a 1.3-point increase in observed no-show rate. Patients without an activated patient portal (MyChart) had approximately 5-percentage-point higher no-show rates across the risk spectrum. Conclusions: Epic’s Risk of Patient No-Show model shows strong correlation with real-world endoscopy attendance and may support predictive overbooking and targeted outreach to improve endoscopy unit efficiency. Given its integration within the EMR, this tool offers a practical framework for operational interventions, though further validation across diverse health systems is warranted.
- 1 May 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Open AccessEstimated no-show rate from the electronic record strongly correlates with endoscopy no-show
Background: High demand for endoscopic procedures contributes to prolonged wait times and limited access to care, particularly in safety-net health systems. Missed appointments, including no-shows and late reschedules, further strain resources and delay diagnosis and treatment. Epic Systems provides a proprietary Risk of Patient No-Show Model, previously validated in primary care settings, but its performance in predicting attendance for endoscopy appointments has not been evaluated. Methods: A retrospective cohort study was conducted among adults scheduled for outpatient endoscopy at a single safety-net hospital between January 1, 2023, and August 1, 2024. Patients aged ≥ 18 years with at least one prior encounter in the electronic medical record (EMR) were included; inpatient procedures and early cancellations (> 2 days before the appointment) were excluded. The primary outcome was appointment completion versus no-show. Epic’s predicted no-show risk, demographic characteristics, procedure type, and patient portal activation status were extracted. The relationship between predicted and observed no-show rates was assessed using the coefficient of determination (R²) and linear regression. Secondary analyses stratified results by patient portal activation. Results: Among 4,658 unique patients, the median age was 59 years, 52.2% were male, and the cohort was racially and linguistically diverse. Overall, 1,493 patients (32.1%) did not attend their scheduled endoscopy. Epic’s predicted no-show risk demonstrated a strong linear correlation with actual no-show rates (R² = 0.87). Observed missed appointment rates followed the equation: Missed Appointment Rate = 1.30 × (Epic Risk) + 0.16 , indicating a baseline no-show rate of 16%. Each percentage-point increase in Epic’s predicted risk corresponded to a 1.3-point increase in observed no-show rate. Patients without an activated patient portal (MyChart) had approximately 5-percentage-point higher no-show rates across the risk spectrum. Conclusions: Epic’s Risk of Patient No-Show model shows strong correlation with real-world endoscopy attendance and may support predictive overbooking and targeted outreach to improve endoscopy unit efficiency. Given its integration within the EMR, this tool offers a practical framework for operational interventions, though further validation across diverse health systems is warranted.
- Open Access
- 14 December 2025
- Published by Elsevier in American Journal of Medicine Open
- Vol. 15, 100123
Influence of Comorbidities on Colorectal Cancer Screening Participation and Mortality
- 14 December 2025
- Published by Elsevier in American Journal of Medicine Open
- Vol. 15, 100123
Open AccessInfluence of Comorbidities on Colorectal Cancer Screening Participation and Mortality
- Open Access
Treatment and Eradication of Helicobacter Pylori in a Safety-Net Health System
Background & Aims: Helicobacter pylori (HP) is the most common chronic bacterial infection worldwide, with a rising resistance rate, although the resistance patterns among minority and immigrant populations are not known. We aimed to determine the failure rate by treatment and race/ethnicity among adult patients with HP infection in a safety-net health system. Methods: We conducted a retrospective cohort study in a safety-net health system from January 2020 to December 2021 of patients diagnosed with HP based on serology, stool antigen, or stomach biopsies who were prescribed antibiotic therapy and had a test of eradication by either stool antigen or histology. The primary outcome was the HP treatment failure rate according to treatment type. Additional subgroup analyses examined the failure rate by age, race/ethnicity, and preferred language. Results: 167 patients carried a diagnosis of HP that was treated with a test of eradication. The median age was 47 (range 18-79); 60% were female, 52% Hispanic, and 25% Asian. 93% received a 14-day course, and 84% were prescribed clarithromycin-based triple therapy. The overall H. pylori treatment failure rate was 18%. The failure rate for quadruple therapy was nominally higher compared to triple therapy (29.2% vs. 16.3%, p=0.13). Younger patients (age ≤ 45) tended to experience treatment failure (24% vs. 13%, p=0.07). Asian (7.3%, p=0.01) and Cantonese-speaking patients (4.2%, p=0.02) had the lowest overall failure rates. Conclusions: In this study of diverse adult patients, triple therapy tended to be more effective than quadruple therapy. Triple therapy was particularly effective for Asian patients. These findings raise the possibility that triple therapy could still serve as a first-line regimen in certain populations.
Open AccessTreatment and Eradication of Helicobacter Pylori in a Safety-Net Health System
Background & Aims: Helicobacter pylori (HP) is the most common chronic bacterial infection worldwide, with a rising resistance rate, although the resistance patterns among minority and immigrant populations are not known. We aimed to determine the failure rate by treatment and race/ethnicity among adult patients with HP infection in a safety-net health system. Methods: We conducted a retrospective cohort study in a safety-net health system from January 2020 to December 2021 of patients diagnosed with HP based on serology, stool antigen, or stomach biopsies who were prescribed antibiotic therapy and had a test of eradication by either stool antigen or histology. The primary outcome was the HP treatment failure rate according to treatment type. Additional subgroup analyses examined the failure rate by age, race/ethnicity, and preferred language. Results: 167 patients carried a diagnosis of HP that was treated with a test of eradication. The median age was 47 (range 18-79); 60% were female, 52% Hispanic, and 25% Asian. 93% received a 14-day course, and 84% were prescribed clarithromycin-based triple therapy. The overall H. pylori treatment failure rate was 18%. The failure rate for quadruple therapy was nominally higher compared to triple therapy (29.2% vs. 16.3%, p=0.13). Younger patients (age ≤ 45) tended to experience treatment failure (24% vs. 13%, p=0.07). Asian (7.3%, p=0.01) and Cantonese-speaking patients (4.2%, p=0.02) had the lowest overall failure rates. Conclusions: In this study of diverse adult patients, triple therapy tended to be more effective than quadruple therapy. Triple therapy was particularly effective for Asian patients. These findings raise the possibility that triple therapy could still serve as a first-line regimen in certain populations.
- Open Access
- 30 September 2025
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (1)
Gastrointestinal MAIT cells in chronic HIV-1 infection
Mucosa-associated invariant T (MAIT) cells are innate-like T cells abundant in mucosal tissues, liver, and blood. MAIT cells recognize riboflavin metabolite-derived microbial antigens displayed by the MHC-I–related protein (MR1) and respond by producing cytokines, killing infected cells, and suppressing microbial growth. We previously demonstrated that MAIT cell numbers and function are reduced in chronic HIV-1, potentially increasing susceptibility to microbial coinfections. Here we assessed colorectal MAIT cells from people living with HIV-1 (PLWH, n = 36) and people without HIV-1 (PWOH, n = 22) by flow cytometry. In PBMCs, MAIT cells were less abundant in PLWH compared to PWOH. However, colorectal MAIT cell percentages were comparable in both groups, suggesting reduced loss from gut compared to blood in HIV-1 infection, or redistribution from blood to mucosae. In both groups, the majority of mucosal MAIT cells expressed CD8 and were enriched for CD8αα; a minority expressed CD4 or were double negative. Colorectal MAIT cells expressed CD69 and CD45RO, indicating a tissue-resident memory phenotype. Mucosal MAIT cells from PWOH expressed high perforin compared to PLWH, although granzyme B was low as compared to blood counterparts. Intracellular cytokine staining revealed robust cytokine production when stimulated with PMA/ionomycin. However, while blood MAIT cells responded strongly to inactivated Escherichia coli, mucosal MAIT cells responded poorly to this stimulus. Thus, gastrointestinal MAIT cells may be partially unresponsive toward commensal microbes, while remaining responsive to other stimuli. These findings provide novel insights into the functional profile of gastrointestinal MAIT cells in the context of chronic HIV-1.
- 30 September 2025
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (1)
Open AccessGastrointestinal MAIT cells in chronic HIV-1 infection
Mucosa-associated invariant T (MAIT) cells are innate-like T cells abundant in mucosal tissues, liver, and blood. MAIT cells recognize riboflavin metabolite-derived microbial antigens displayed by the MHC-I–related protein (MR1) and respond by producing cytokines, killing infected cells, and suppressing microbial growth. We previously demonstrated that MAIT cell numbers and function are reduced in chronic HIV-1, potentially increasing susceptibility to microbial coinfections. Here we assessed colorectal MAIT cells from people living with HIV-1 (PLWH, n = 36) and people without HIV-1 (PWOH, n = 22) by flow cytometry. In PBMCs, MAIT cells were less abundant in PLWH compared to PWOH. However, colorectal MAIT cell percentages were comparable in both groups, suggesting reduced loss from gut compared to blood in HIV-1 infection, or redistribution from blood to mucosae. In both groups, the majority of mucosal MAIT cells expressed CD8 and were enriched for CD8αα; a minority expressed CD4 or were double negative. Colorectal MAIT cells expressed CD69 and CD45RO, indicating a tissue-resident memory phenotype. Mucosal MAIT cells from PWOH expressed high perforin compared to PLWH, although granzyme B was low as compared to blood counterparts. Intracellular cytokine staining revealed robust cytokine production when stimulated with PMA/ionomycin. However, while blood MAIT cells responded strongly to inactivated Escherichia coli, mucosal MAIT cells responded poorly to this stimulus. Thus, gastrointestinal MAIT cells may be partially unresponsive toward commensal microbes, while remaining responsive to other stimuli. These findings provide novel insights into the functional profile of gastrointestinal MAIT cells in the context of chronic HIV-1.
- Open Access
CLINICAL DIAGNOSIS CODES IDENTIFY PATIENTS UNLIKELY TO RECEIVE ORDERS FOR FECAL IMMUNOCHEMICAL TESTS
Introduction: Organized screening programs automate fecal immunochemical test (FIT) outreach based on chronological age. However, providers and patients may defer screening due to coexisting conditions, which can be captured by International Classification of Disease, 10 th revision (ICD-10) codes. We sought to identify codes associated with not having a FIT order. Methods: We included screen-eligible patients with a primary care visit between June 2022 and June 2023. We enumerated and compared the frequency of each ICD-10 code between patients with and without a FIT ordered. We conducted a subgroup analysis including only those with a Charlson comorbidity index (CCI) <5. Results: We identified 15,020 screen-eligible patients, with 10,187 (67.8%) patients having had a FIT order and 4,833 (32.3%) patients without a FIT order. Of the 1,215 ICD-10 codes examined, 96 were significantly associated with not having a FIT order. One broad category of codes pertained to digestive diseases such as benign and malignant colonic neoplasms (ICD-10 code C18, odds ratio (OR) 0.06, 95% CI [0.001-0.44]) and diverticular disease (K57, OR 0.26 [0.18-0.36]). Another category was comorbid conditions which included frailty (R54, OR 0.14 [0.03-0.55]) and paralysis (G82, OR 0.14 [0.03-0.55]). Those with acute conditions such as cervical fractures (S12, OR 0.23 [0.10-0.48]) and cryptococcosis (B45, OR 0.05 [0.001-0.38]) were also less likely to have a FIT order. Among the patients with CCI<5, 41 codes were significantly associated with not having a FIT order, including heart failure (I50, OR 0.55 [0.43-0.71]) and chronic kidney disease (N18, OR 0.58 [0.43-0.77]). Conclusion: Patients deferred from screening were more likely to have ICD-10 codes signifying digestive diseases, comorbidities, and acute conditions. Even among patients with fewer co-morbid conditions, we identified health conditions that were associated with screening deferral. Future work should consider whether screening programs could incorporate ICD-10 codes to align FIT outreach more closely with provider and patient preferences.
Open AccessCLINICAL DIAGNOSIS CODES IDENTIFY PATIENTS UNLIKELY TO RECEIVE ORDERS FOR FECAL IMMUNOCHEMICAL TESTS
Introduction: Organized screening programs automate fecal immunochemical test (FIT) outreach based on chronological age. However, providers and patients may defer screening due to coexisting conditions, which can be captured by International Classification of Disease, 10 th revision (ICD-10) codes. We sought to identify codes associated with not having a FIT order. Methods: We included screen-eligible patients with a primary care visit between June 2022 and June 2023. We enumerated and compared the frequency of each ICD-10 code between patients with and without a FIT ordered. We conducted a subgroup analysis including only those with a Charlson comorbidity index (CCI) <5. Results: We identified 15,020 screen-eligible patients, with 10,187 (67.8%) patients having had a FIT order and 4,833 (32.3%) patients without a FIT order. Of the 1,215 ICD-10 codes examined, 96 were significantly associated with not having a FIT order. One broad category of codes pertained to digestive diseases such as benign and malignant colonic neoplasms (ICD-10 code C18, odds ratio (OR) 0.06, 95% CI [0.001-0.44]) and diverticular disease (K57, OR 0.26 [0.18-0.36]). Another category was comorbid conditions which included frailty (R54, OR 0.14 [0.03-0.55]) and paralysis (G82, OR 0.14 [0.03-0.55]). Those with acute conditions such as cervical fractures (S12, OR 0.23 [0.10-0.48]) and cryptococcosis (B45, OR 0.05 [0.001-0.38]) were also less likely to have a FIT order. Among the patients with CCI<5, 41 codes were significantly associated with not having a FIT order, including heart failure (I50, OR 0.55 [0.43-0.71]) and chronic kidney disease (N18, OR 0.58 [0.43-0.77]). Conclusion: Patients deferred from screening were more likely to have ICD-10 codes signifying digestive diseases, comorbidities, and acute conditions. Even among patients with fewer co-morbid conditions, we identified health conditions that were associated with screening deferral. Future work should consider whether screening programs could incorporate ICD-10 codes to align FIT outreach more closely with provider and patient preferences.